170
Participants
Start Date
November 30, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
Rasagiline
Placebo
Teva Investigational Site 036, Birmingham
Teva Investigational Site 047, Sun City
Teva Investigational Site 004, Irvine
Teva Investigational Site 016, La Jolla
Teva Investigational Site 042, Long Beach
Teva Investigational Site 041, San Bernardino
Teva Investigational Site 048, Denver
Teva Investigational Site 038, Englewood
Teva Investigational Site 035, Danbury
Teva Investigational Site 034, Manchester
Teva Investigational Site 037, New London
Teva Investigational Site 026, Washington D.C.
Teva Investigational Site 015, Boca Raton
Teva Investigational Site 021, Jacksonville
Teva Investigational Site 033, Ormond Beach
Teva Investigational Site 020, Port Charlotte
Teva Investigational Site 017, St. Petersburg
Teva Investigational Site 019, Atlanta
Teva Investigational Site 003, Chicago
Teva Investigational Site 006, Chicago
Teva Investigational Site 008, Chicago
Teva Investigational Site 025, Kansas City
Teva Investigational Site 009, Lexington
Teva Investigational Site 046, Baton Rouge
Teva Investigational Site 024, Boston
Teva Investigational Site 031, Las Vegas
Teva Investigational Site 030, New Brunswick
Teva Investigational Site 014, Albany
Teva Investigational Site 045, Commack
Teva Investigational Site 013, Kingston
Teva Investigational Site 010, New York
Teva Investigational Site 040, New York
Teva Investigational Site 022, Asheville
Teva Investigational Site 005, Raleigh
Teva Investigational Site 018, Toledo
Teva Investigational Site 028, Philadelphia
Teva Investigational Site 012, Nashville
Teva Investigational Site 002, San Antonio
Teva Investigational Site 011, Salt Lake City
Teva Investigational Site 001, La Crosse
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY